Tumor-Infiltrating Macrophages in Post-Transplant, Relapsed Classical Hodgkin Lymphoma Are Donor-Derived

Genevieve M. Crane1,*, Mark A. Samols1, Laura A. Morsberger1, Raluca Yonescu1, Michele L. Thiess1, Denise A. S. Batista1, Yi Ning1, Kathleen H. Burns1, Milena Vuica-Ross1, Michael J. Borowitz1, Christopher D. Gocke1, Richard F. Ambinder2‡, Amy S. Duffield1‡*

1 Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America, 2 Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America

These authors contributed equally to this work.

‡ These authors also contributed equally to this work.

* adduffiel@jhmi.edu

Abstract

Tumor-associated inflammatory cells in classical Hodgkin lymphoma (CHL) typically outnumber the neoplastic Hodgkin/Reed-Sternberg (H/RS) cells. The composition of the inflammatory infiltrate, particularly the fraction of macrophages, has been associated with clinical behavior. Emerging work from animal models demonstrates that most tissue macrophages are maintained by a process of self-renewal under physiologic circumstances and certain inflammatory states, but the contribution from circulating monocytes may be increased in some disease states. This raises the question of the source of macrophages involved in human disease, particularly that of CHL. Patients with relapsed CHL following allogeneic bone marrow transplant (BMT) provide a unique opportunity to begin to address this issue. We identified 4 such patients in our archives. Through molecular chimerism and/or XY FISH studies, we demonstrated the DNA content in the post-BMT recurrent CHL was predominantly donor-derived, while the H/RS cells were derived from the patient. Where possible to evaluate, the cellular composition of the inflammatory infiltrate, including the percentage of macrophages, was similar to that of the original tumor. Our findings suggest that the H/RS cells themselves define the inflammatory environment. In addition, our results demonstrate that tumor-associated macrophages in CHL are predominantly derived from circulating monocytes rather than resident tissue macrophages. Given the association between tumor microenvironment and disease progression, a better understanding of macrophage recruitment to CHL may open new strategies for therapeutic intervention.
Introduction

Lymph nodes involved by classical Hodgkin lymphoma (CHL) typically contain relatively few neoplastic Hodgkin/Reed-Sternberg (H/RS) cells, which are scattered throughout a mixed inflammatory background composed of lymphocytes, macrophages, neutrophils, eosinophils and plasma cells. The H/RS cells can comprise as little as 1% of the cellularity [1]. While only the H/RS cells are neoplastic, the composition of the inflammatory background correlates with prognosis and response to treatment [2–10]. It is unclear to what extent the H/RS cells themselves dictate the inflammatory environment.

Of particular interest are the tumor-associated macrophages and their source as increased numbers of tumor-associated macrophages correlate with a poor prognosis in patients with CHL [11–16]. While tissue macrophages had long been presumed to be derived from circulating monocytes, recent evidence suggests that monocytes do not substantially contribute to macrophage populations in most tissues during normal homeostasis or certain inflammatory states [17]. Instead, it appears that macrophage populations within tissues maintain themselves predominantly by self-renewal, after being seeded in those locations by yolk sac precursors during embryonic development [18–20]. By contrast, tumor associated macrophages in the context of solid tumors [21–23] and inflammatory reactions associated with pathologic processes, such as atherosclerosis [24], are predominantly derived from circulating monocytes.

In addition, while self-renewal of resident macrophages may enable recovery in response to various forms of tissue injury [18], lethal radiation prior to bone marrow transplant (BMT) results in gradual replacement of tissue macrophages (with the exception of microglia) by donor monocytes in both mouse models [18, 25] and human patients [26, 27]. However, host macrophages may persist, particularly when fractionated doses of radiation are given, and be capable of repopulating the tissue [28]. Even when largely ablated, a small population of residual host macrophages may serve as antigen presenting cells and development of graft versus host disease [29].

The complex interplay between residual/recovering tissue macrophages and colonizing donor monocytes following BMT is of particular interest in recurrent CHL. Recurrent CHL often involves tissues with a large resident macrophage population such as lung and liver. Given the association with macrophage frequency and disease prognosis, we sought to further understand this process, including whether the inflammatory environment may change post-transplant. We characterize the inflammatory infiltrate in pre- and post-BMT tumor specimens in patients who had received an allogeneic BMT and investigate the origin of the inflammatory cells (donor or recipient) in the post-BMT specimens.

Materials and Methods

Prior to commencing the study, approval was obtained from the Johns Hopkins Hospital Institutional Review Board (JHH IRB) under the IRB-approved protocol IRB NA_00083069. Per the JHH IRB, specific oral or written consent was not required for inclusion of specimens in this retrospective study, as the findings do not affect either diagnosis or treatment and both the diagnosis and treatment plans were established prior to and independent of the study findings. The pathology database was then searched to identify patients with CHL who were treated with an allogeneic BMT at our institution and subsequently developed relapsed disease. Clinical data were reviewed by one of the authors (A.S.D.) in accordance with IRB-approved protocol. Decalcified bone marrow biopsy specimens were excluded from the study.

Formalin-fixed and paraffin-embedded (FFPE) tissue was used to perform XY chromosome studies using fluorescence in situ hybridization (FISH; CEP X SpectrumOrange/Y SpectrumGreen Direct Labeled Fluorescent DNA Probe Kit, Abbott Molecular, Des Plaines, IL) in...
patients who received a sex mismatched BMT. Representative fields were chosen based on the corresponding H&E stained sections, and XY FISH images were captured with a fluorescence microscope. XY FISH was also performed subsequent to standard immunohistochemical staining for CD68 on the same slide.

Molecular chimerism studies (AmpF1STR Identifiler, Applied Biosystems, Foster City, CA) were performed on the post-transplant FFPE tissue in 3 of the 4 patients. This system uses PCR and capillary electrophoresis (ABI 3130xl, Applied Biosystems, Foster City, CA) to determine the length of 15 tetranucleotide short tandem repeats (STRs) in order to generate a molecular "signature" for the patient and donor. The relative percentages of donor and patient DNA in the post-BMT CHL samples were determined using the patient and donor STR profiles that were performed prior to the BMT.

The FFPE tissue was also subjected to hematoxylin and eosin (H&E) staining as well as immunohistochemical staining using routine methods for clinical diagnosis. All antibodies were from Ventana (CD15, 760–2504; CD30, 790–2926; CD68, 790–2931; CD20, 760–2531; Tucson, AZ) with the exception of CD3 (ORG-8982, Leica, Bannock Burn, IL).

Results

Four patients were identified that had relapsed CHL after an allogeneic BMT and also had post-BMT FFPE tissue involved by CHL available in our archives (Table 1). Two of these patients also had FFPE tissue available that was involved by CHL from before the BMT (Patients A and B).

Three patients had undergone myeloablative transplants (Patients B, C and D), and one patient (Patient A) had a non-myeloablative (reduced intensity) transplant. Three of the four patients had opposite sex donors: patients (Patients A and C) were male but had a female donor and patient (D) was a female but had a male donor. Two of the patients (B and D) had bone marrow chimerism studies available near the time of relapse. In patient B, studies performed both one month before relapse and one month after relapse (but before the initiation of treatment) showed approximately 10% patient DNA and 90% donor DNA. Patient D had 100% donor DNA with no patient DNA detected both 8 months prior to relapse and 2 months after relapse.

To assess the origin of the inflammatory infiltrate in the recurrent lymphoma we performed XY FISH on post-BMT tumor from patients A, C and D. Samples from all three patients demonstrated that the inflammatory infiltrate was largely composed of donor derived inflammatory cells (Fig 1, Fig 2, S1 Fig and S3 Fig). Scattered larger cells derived from the patient were present, which were compatible with HRS cells based on morphology and evaluation of adjacent sections stained for CD30 (Fig 1 and S1 Fig).

To confirm the FISH findings as well as to investigate the composition of the tumor in the patient with a same-sex donor (Patient B), molecular chimerism studies were performed on 3 of the 4 patients (excluding patient D). For all three, the molecular identity testing showed that the majority of the cells in the tumor were of donor origin (Patient A 89% donor; Patient B 72% donor; Patient C 62% donor) (Fig 3).

For the two patients where pre- and post-BMT tissue was available (Patients A and B), IHC stains were performed to visualize the neoplastic cells and the composition of the inflammatory infiltrate (Fig 4). The percentage of CD68-positive macrophages, CD3-positive T-cells, CD8-positive T-cells, and CD20-positive B-cells was estimated by 5 experienced hematologic pathologists (M.V.-R., C.D.G., K.H.B., M.J.B., and A.S.D.) who did not know the identity of the specimens. Both patients' specimens showed a similar composition of CD68-positive macrophages and CD8-positive T-cells as a percentage of total T-cells in the pre- and post-BMT
In both patients B-cells were more numerous in the post-BMT sample, although the significance of this finding is unclear. Notably, the initial treatment for patient A included rituximab prior to BMT. The inflammatory infiltrate was also characterized for patient A at the time of the 4th relapse, though the patient had been treated with the anti-PD-1 monoclonal antibody nivolumab prior to the biopsy (S4 Fig).

**Discussion**

In this study we utilized post-BMT tumor specimens in order to more fully characterize the relationship between H/RS cells and the tumor-associated inflammatory cells, in particular the origin of the tumor-associated macrophages. These findings support the idea that H/RS cells, perhaps through cytokines and chemokines, actively recruit and define the inflammatory microenvironment [30–35]. In particular, the H/RS cells appear to recruit donor-derived circulating monocytes from the bone marrow as opposed to stimulating the proliferation of resident macrophages within the tissue. For example, in Patient A, FISH showed only rare cells with patient DNA while tumor-infiltrating macrophages comprised about 15% of the cellularity in tumor (Table 2).
Macrophages that were donor-derived could also be readily identified by co-staining the same slide for CD68 by immunohistochemistry and XY FISH (Patient D, Fig 2) and appeared to comprise the vast majority of the macrophages within the lesion. Additionally, we found that the composition of the inflammatory infiltrate was very similar in the pre- and post-BMT samples where evaluable. The percentage of macrophages for the two patients examined in this manner fell into the “intermediate risk” category as defined by Steidl, et al. with between 5 and 25% macrophages [13] and similar percentages in the relapsed...
Fig 2. Tumor-infiltrating macrophages in recurrent Hodgkin lymphoma are predominantly donor- and, therefore, bone marrow-derived. A portion of the same field highlighted in Fig 1A (white box) is shown at higher magnification. Prior to analysis by XY FISH, the same slide was stained for CD68 using standard immunohistochemical techniques in order to identify macrophages (A). The
images of the DAPI nuclear stain and the CD68 cytoplasmic stain are overlaid (B) to better identify individual cells in the corresponding FISH images (C). Where possible to discern, the tumor-infiltrating macrophages are all derived from the male donor (arrows, XY, red and green). However, by this method we found that in 21 +/- 4% of DAPI-positive nuclei, it was not possible to score X, Y status due to sectioning and/or other technical limitations. Of note, this patient had 100% donor chimerism in her bone marrow when tested near the time of this biopsy. H/RS cells (Fig 1 and S1 Fig) and areas of residual, uninvolved lung tissue were female (not shown). An overview of the density of macrophage infiltrate is shown in S2 Fig.

doi:10.1371/journal.pone.0163559.g002

Fig 3. Molecular diagnostic studies show that the majority of cells in post-BMT tumor are derived from the donor. Molecular chimerism studies of pre- and post-BMT tumor (Patient C) are shown. Patient and donor specific peaks are shown in (A) and (B), respectively. Specific peaks derived from the patient DNA are highlighted by black arrows in the post-BMT tumor specimen (C). At the time of relapse this tumor specimen was 62% donor.

doi:10.1371/journal.pone.0163559.g003
Monocyte Origin of Tumor-Infiltrating Macrophages in Recurrent Hodgkin Lymphoma

specimens post-BMT. The percentage of CD8-positive T-cells also remained similar pre- and post-BMT, suggesting that the H/RS cells are recruiting a specific complement of inflammatory cells. Of note, EBV may affect the inflammatory environment by altering cytokine expression [36] and has been associated with increased CD8+ T-cells, increased LAG-3-positive regulatory T-cells and increased macrophage recruitment [11, 37]. However, in this series, only one of the four cases was EBV-associated, and a corresponding primary diagnostic specimen was not available for comparison in this patient. Even in the absence of EBV, studies of the inflammatory environment in CHL have demonstrated an association with immunosuppressive molecules and an impaired T-cell response [37, 38]. For example, increased expression of immune modulators such as indoleamine 2,3-dioxygenase (IDO) was associated with worse clinical outcome. IDO expression strongly correlated with extent of macrophage infiltration and was expressed by macrophage/monocyte-derived cells [38]. While it is possible that BMT may result in an alteration in the tumor microenvironment to a more pro-inflammatory state with graft versus tumor effect, the similar inflammatory environments pre and post-transplant in terms of percent of tumor-infiltrating macrophages, and fractions of CD4 and CD8+ T-cells argue against this possibility. Nonetheless, this does not rule out the possibility that some patients may have a favorable change in their immune response post-transplant.

One potential limitation on the generalizability of this study for understanding tumor-infiltrating macrophage recruitment to the CHL microenvironment is the demonstration in prior studies that total body irradiation is associated with gradual replacement of tissue macrophages by bone marrow-derived monocytes [18, 25–27]. However, our study did include one patient who had undergone a non-myeloablative BMT (Patient A), and even in that patient, the inflammatory infiltrate remained predominantly donor-derived (S3 Fig). This suggests the recruitment of bone marrow derived monocytes to recurrent CHL is not a mere artifact of the BMT conditioning regimen.

While the number of cases is small, our findings raise the possibility of novel treatment strategies for recurrent CHL, including the potential to pharmacologically inhibit monocyte recruitment to tumor lesions to slow or alter disease progression [39,40].

Table 2. Composition of the Inflammatory Infiltrate.

| Sample  | CD68+ Cells | CD8+ T-cells | CD3:CD20 ratio |
|---------|-------------|--------------|----------------|
| pt A pre| 20%         | 15%          | 6.5:1          |
| pt A post| 15%        | 20%          | 1.7:1          |
| pt B pre| 10%         | 67%          | 8.4:1          |
| pt B post| 5%          | 67%          | 1:2.2          |

Semi-quantitative measurements of CD68-positive macrophages, CD8-positive T-cells, and the CD3 to CD20 ratio for the pre- and post-BMT samples from two patients with available pre-BMT CHL tumor specimens are shown. The provided values are the median of semi-quantitative estimates from five hematologic pathologists.

doi:10.1371/journal.pone.0163559.t002
Supporting Information

S1 Fig. Large atypical cells consistent with H/RS cells are patient-derived in recurrent Hodgkin lymphoma following BMT. A separate area of recurrent CHL involving the lung from patient D is shown (compared to Fig 1). XY FISH revealed that large atypical nuclei were predominantly derived from the female patient (XX, red). In addition, there were smaller patient-derived nuclei (XX, red) with a distribution consistent with endothelial cells. However, the majority of the surrounding inflammatory cells appeared donor-derived (XY, red and green). This corresponded to 78% of total nuclei (as highlighted by DAPI), including only cells where possible it was possible to identify distinct FISH signals. Adjacent sections show H/RS cells by CD30 staining and histomorphology (H&E) with a similar distribution to the large atypical, patient-derived cells.

(TIF)

S2 Fig. Numerous macrophages are present with the inflammatory infiltrate of recurrent Hodgkin lymphoma. The same image shown in Fig 1A is displayed for orientation (A), representing recurrent CHL involving the lung in Patient D. The corresponding CD68 immunostain of the same tissue section (B) reveals numerous tumor-infiltrating macrophages throughout the lesion comprising approximately 10–20% of the cellularity.

(TIF)

S3 Fig. ISH studies from a patient with a non-myeloablative (reduced intensity) BMT. Even in the reduced intensity BMT setting, the majority of cells in the recurrent tumor are donor-derived. XY FISH studies of the pre- and post-BMT tumor from Patient A are shown. Nuclei are stained with DAPI (blue). Red and green signals correspond to the probes on the X and Y chromosomes, respectively. The pre-BMT tissue (cervical lymph node) demonstrates both X and Y chromosomes in all cells whereas the post-BMT tissue (portal lymph node) shows that most cells are XX (red; donor, 85% of those that could be identified) with only scattered large XY (red and green; patient, 15% of those that could be identified) cells. In 21% of nuclei, the X, Y FISH probes could not be definitively evaluated due to the plane of section.

(TIF)

S4 Fig. Inflammatory cells in a post-BMT specimen status post checkpoint inhibitor therapy. Representative high power fields from an axillary lymph node involved by CHL from Patient A post-BMT and post-treatment with the anti-PD-1 monoclonal antibody nivolumab (4th relapse; 200x). There is a suggestion of a decrease in the percentage of CD8+ cells as compared to both the initial pre and post-BMT specimens, but the findings are otherwise similar. All antibodies were from Ventana (Pax-5, 790–4420; CD4, 790–4423; CD8, 790–4460; PD-1, 760–4895; Tuscon, AZ), with the exception of lymphocyte-activation protein 3 (Lag3, 17B4; LS Bio, Seattle, WA) and indoleamine 2,3-dioxegenase (IDO, AB 9900, Millipore, Billerica, MA). IDO is visualized as red staining.

(TIF)

Acknowledgments

This research was funded in part by an award from the Joseph C. Eggleston Fund in Surgical Pathology (M.A.S.), a Mabel Smith Research and Education Award (G.M.C.) and R21CA188824 (R.F.A).

Author Contributions

Conceptualization: GMC MAS ASD RFA.
Formal analysis: GMC MAS ASD LAM YN.
Funding acquisition: ASD RFA GMC MAS.
Investigation: GMC MAS ASD KHB MVR MJB CDG RY YN LAM.
Methodology: GMC MAS ASD RFA.
Project administration: ASD RFA.
Resources: ASD RFA.
Supervision: ASD MJB RFA.
Validation: GMC MAS ASD RFA KHB MVR MJB CDG RY MLT DASB YN.
Visualization: GMC MAS ASD.
Writing – original draft: GMC MAS ASD.
Writing – review & editing: GMC ASD RFA.

References
1. Kuppers R. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009;491–6. doi: 10.1182/asheducation-2009.1.491 PMID: 20008234.
2. Alavaikko MJ, Blanco G, Aine R, Lehtinen T, Fellbaum C, Taskinen PJ, et al. Follicular dendritic cells have prognostic relevance in Hodgkin’s disease. Am J Clin Pathol. 1994; 101(6):761–7. doi: 10.1093/ajcp/101.6.761 PMID: 8209866.
3. Alvaro T, Lejeune M, Salvador MT, Bosch R, Garcia JF, Jaen J, et al. Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005; 11(4):1467–73. doi: 10.1158/1078-0432.CCR-04-1869 PMID: 15746048.
4. Alvaro-Naranjo T, Lejeune M, Salvador-Usach MT, Bosch-Princep R, Reverter-Branchat G, Jaen-Martinez J, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin’s lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma. 2005; 46(11):1581–91. doi: 10.1080/10428190500220654 PMID: 16236613.
5. Asano N, Oshiro A, Matsuo K, Kagami Y, Ishida F, Suzuki R, et al. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin’s lymphoma: a clinicopathologic study. J Clin Oncol. 2006; 24(28):4626–33. doi: 10.1200/JCO.2006.06.188096 PMID: 16954517.
6. Chetaille B, Bertucci F, Finetti P, Esterini B, Stamatoulas A, Picquenot JM, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood. 2009; 113(12):2765–3775. doi: 10.1182/blood-2008-07-168096 PMID: 19096012.
7. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009; 27 (1):31–9. doi: 10.1002/hnj.878 PMID: 18924115.
8. Tudor CS, Distel LV, Eckhardt J, Hartmann A, Niedobitek G, Buettner M. B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction. Hum Pathol. 2013; 44(11):2475–86. doi: 10.1016/j.humpath.2013.06.006 PMID: 24029709.
9. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dimhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica. 2008; 93 (2):193–200. doi: 10.3324/haematol.11702 PMID: 18223287.
10. von Wasielewski R, Seth S, Franklin J, Fischer R, Hubner K, Hansmann ML, et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin’s disease, allowing for known prognostic factors. Blood. 2000; 95(4):1207–13. PMID: 10666192.
11. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d’Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin’s lymphoma. Haematologica. 2011; 96(2):269–76. doi: 10.3324/haematol.2010.031542 PMID: 21071500; PubMed Central PMCID: PMC3031695.
12. Ree HJ, Kadin ME. Macrophage-histiocytes in Hodgkin’s disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer. 1985; 56(2):333–8. doi: 10.1002/1097-0142(19850715)56:2%3C333::aid-cncr2820560222%3E3.0. co;2-0 PMID: 2408733.

13. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010; 362(10):875–85. doi: 10.1056/NEJMoa0905680 PMID: 20220182; PubMed Central PMCID: PMC2897174.

14. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012; 120(16):3280–7. doi: 10.1182/blood-2012-04-421057 PMID: 22948049; PubMed Central PMCID: PMC3476539.

15. Tudor CS, Bruns H, Daniel C, Distel LV, Hartmann A, Gerbitz A, et al. Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma. PLoS One. 2014; 9(12):e114345. doi: 10.1371/journal.pone.0114345 PMID: 25470820; PubMed Central PMCID: PMC4255018.

16. Barros MH, Hassan R, Niedobitek G. Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res. 2012; 18(14):3762–71. doi: 10.1158/1078-0432.CCR-12-0129 PMID: 22645050.

17. Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol. 2014; 14(6):392–404. doi: 10.1038/nri3671 PMID: 24854589.

18. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013; 38(4):792–804. doi: 10.1016/j.immuni.2013.04.004 PMID: 23601688; PubMed Central PMCID: PMC3853406.

19. Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013; 38(1):79–91. doi: 10.1016/j.immuni.2012.12.001 PMID: 23273845; PubMed Central PMCID: PMC3908543.

20. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013; 496(7446):445–55. doi: 10.1038/nature12034 PMID: 23619691; PubMed Central PMCID: PMC3725458.

21. Sica A, Schioppa T, Mantovani A, Allavena P. Tumor-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancercer. 2006; 42(6):717–27. doi: 10.1016/j.ejca.2006.01.003 PMID: 16520032.

22. Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P, et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A. 2006; 103(27):10340–5. doi: 10.1073/pnas.0604260103 PMID: 16801531; PubMed Central PMCID: PMC1502459.

23. Haniffa M, Ginhoux F, Wang XN, Bigley V, Abel M, Dimmick J, et al. Differentiated rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. J Exp Med. 2009; 206(2):371–85. doi: 10.1084/jem.20081633 PMID: 19171766; PubMed Central PMCID: PMC2646566.

24. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gioglini A, Carbone A, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in...
tumor cell growth and microenvironmental interactions. Int J Cancer. 2008; 122(4):769–76. doi: 10.1002/ijc.23119 PMID: 17935139.

31. Fischer M, Juremalm M, Olsson N, Backlin C, Sundstrom C, Nilsson K, et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer. 2003; 107(2):197–201. doi: 10.1002/ijc.11370 PMID: 12949794.

32. Hanamoto H, Nakayama T, Miyazato H, Takegawa S, Hieshima K, Tatsumi Y, et al. Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin’s disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol. 2004; 164(3):997–1006. doi: 10.1016/S0002-9440(10)63187-2 PMID: 14982853; PubMed Central PMCID: PMC1614715.

33. Jundt F, Anagnostopoulos I, Bommert K, Emmerich F, Muller G, Foss HD, et al. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood. 1999; 94(6):2065–71. PMID: 10477736.

34. Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008; 103(6):1428–35; quiz 36. doi: 10.1111/j.1572-0241.2008.01836.x PMID: 18494836.

35. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin’s lymphoma. Am J Pathol. 1999; 154(6):1685–91. doi: 10.1016/S0002-9440(10)65424-7 PMID: 10362793; PubMed Central PMCID: PMC1876772.

36. Herling M, Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Kliche KO, Nadali G, et al. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res. 2003; 9(6):2114–20. PMID: 12796376.

37. Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. 2006; 108(7):2280–9. doi: 10.1182/blood-2006-04-015164 PMID: 16757886.

38. Choe JY, Yun JY, Jeon YK, Kim SH, Park G, Huh JR, et al. Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC Cancer. 2014; 14:335. doi: 10.1186/1471-2407-14-335 PMID: 24886161; PubMed Central PMCID: PMCPMC4026588.

39. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. 2013; 19(13):3404–15. doi: 10.1158/1078-0432.CCR-13-0525 PMID: 23853148; PubMed Central PMCID: PMC3700620.

40. Panni RZ, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy. 2013; 5(10):1075–87. doi: 10.2217/imt.13.102 PMID: 24088077; PubMed Central PMCID: PMC3867255.